

MCQ Question · mcqquestion.com

Kiran Mazumdar-Shaw

Free · Share

Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw founded Biocon in 1978, in the garage of her rented house in Bengaluru. She built it into India’s first biotech company to go public. She became the country’s first self-made woman billionaire. She is widely seen as the founder of India’s biotechnology industry.

At a Glance

Four facts to hold on to.

01
1978

Biocon founded with ₹10,000.

02
2004

IPO oversubscribed 33 times; Insugen launched.

03
$5.5 bn

Value placed on Biocon Biologics in the 2025-26 deal.

04
29 Jun 2026

Date the consolidation completed.

Biosimilar A cheaper version of a complex biologic drug.
Insugen India’s first indigenous human insulin.
Master brewer A trained expert in brewing and malting.

Othmer Gold MedalA science and chemistry honour she holds.

Part 1: Founding and First Breakthroughs

Must Know

Education and founding

- Kiran Mazumdar-Shaw was born on 23 March 1953, in Bangalore, then in Mysore State.
- She earned a Bachelor's degree in zoology, with honours, from Bangalore University in 1973.
- In 1975, she trained as a master brewer, earning a postgraduate diploma in malting and brewing from Ballarat College, Melbourne.
- In 1978, at 25, she founded Biocon in the garage of her rented house in Bengaluru, with just ₹10,000 in capital.

From enzymes to biopharmaceuticals

- Biocon first made industrial enzymes. In 1979, it became the first Indian company to export them to the US and Europe.
- In 2004, Biocon went public as the first Indian biotech company to have an IPO. It was oversubscribed 33 times.
- The same year, it developed India's first human insulin. That moved it from enzymes into biopharmaceuticals.
- She became India's first self-made woman billionaire, largely on the strength of Biocon's growth.

Remember: 1978 Biocon. 1979 enzyme exports. 2004 IPO and Insugen. 2025-26 Biocon Biologics consolidation.

Quick check 1. Biocon's 2004 IPO made it the first Indian company of any kind to go public. *(True or False?)* See answer ↓

Part 2: Struggle, Biosimilars and Honours

Good to Know

Early gender discrimination

- In Biocon's early years, investors hesitated.
- Some vendors refused to deal with her unless she hired a male manager.
- She struggled to find staff willing to work for a woman-led company, in the business climate of the late 1970s.

The shift to biosimilars

- Biosimilars are more affordable versions of complex biologic drugs, made from living cells, not chemical synthesis.
- Biocon's biosimilars include affordable versions of major global drugs originally sold as Humira, Herceptin and Stelara.
- Biocon Biologics is the separate subsidiary that runs the biosimilars business.

Why Insugen mattered

- Insugen launched in 2004 at a much lower price than imported insulin.
- That forced international insulin companies to cut their own prices in India.
- The old page said it also gave the government confidence to put human insulin under price control. I could not verify that link.

Honours

- India: the Padma Shri in 1989 and the Padma Bhushan in 2005, India's fourth- and third-highest civilian awards.
- She also holds the Othmer Gold Medal, for contributions to science and chemistry.
- France made her a Chevalier de l'Ordre National de la Légion d'Honneur in 2016.
- In 2020, she received Australia's Order of Australia, for strengthening India-Australia ties.

> **Quick check 2.** Biosimilars are cheaper versions of complex biologic drugs made from living cells. *(True or False?)* See answer ↓

Part 3: What Her Story Shows

Great to Know

A career that traces India's biotech industry

- Her career follows India's own biotech arc, from basic enzyme making in the 1970s to complex biosimilars today.
- See Biotechnology and Department of Biotechnology (DBT) for how the wider industry is organised.
- Biocon is based in Bengaluru. See Karnataka: Silicon Valley of India and the Vijayanagara Legacy.

What the 2004 listing proved

- It helped show that an Indian company could build and sell advanced biopharmaceutical science.
- That was different from just making generic small-molecule drugs cheaply.

A landmark case for women in business

- Her early struggle to be taken seriously is often cited as a landmark case in Indian business.
- It came well before "women in STEM" became a mainstream policy topic.

Part of a wider global trend

- Biocon's shift to biosimilars mirrors a global trend.
- As patents on costly biologic drugs expire, companies race to make cheaper, close versions available to more patients.

> **Think it through: Why did a garage start-up begin with enzymes, not drugs?**
>
> Enzymes needed little capital and had ready industrial buyers. Cash from them later paid for harder drug science.

Part 4: Current Affairs and Exam Traps

Great to Know

A $5.5 billion consolidation

- On 6 December 2025, Biocon Limited announced it would make Biocon Biologics a wholly-owned subsidiary again. It valued the biosimilars unit at $5.5 billion.
- The deal had two parts: a share swap buying out minority investors, and a separate $815 million buyout of Viatris's residual stake.
- The original target for the consolidation was 31 March 2026. A milestone dated 29 June 2026 came later than that target.
- Biocon's generics and biosimilars businesses now sit under one roof, strengthening its position in diabetes, oncology and immunology drugs.

Exam traps

- No UPSC question has directly tested her biography so far.
- Precise claim: she is India's first self-made woman billionaire, and Biocon is India's first biotech company to go public. It is not the first Indian company of any kind to go public.
- Date trap: the 2004 IPO and the 2004 Insugen launch are two distinct milestones in one year.
- Do not confuse the 2004 IPO with the 2025-26 deal that made Biocon Biologics wholly-owned again.
- This article's old version named no source links for the figures above.

Quick Q&A

When was Biocon founded?

1978.

What was its first export?

Industrial enzymes, 1979.

What did Biocon launch in 2004?

Insugen, India’s first human insulin.

How much was the IPO oversubscribed?

33 times.

When did the Biocon Biologics deal complete?

29 June 2026.

🎲 Practice: Kiran Mazumdar-Shaw

8 verified questions from this topic.

🎲 More Indian Economy Practice

Related Topics

All Indian Economy Articles

Biotechnology

Department of Biotechnology (DBT)

Karnataka: Silicon Valley of India and the Vijayanagara Legacy

Practice MCQs

1. At what age did Kiran Mazumdar-Shaw found Biocon, and in which year?

A. 22, in 1975

B. 30, in 1983

C. 28, in 1981

D. 25, in 1978

See answer ↓

2. What was Biocon's original business when Kiran Mazumdar-Shaw founded it in 1978?

A. Vaccine manufacturing

B. Industrial enzymes

C. Biosimilar cancer drugs

D. Human insulin

See answer ↓

3. When Biocon went public in 2004, what made the listing historically significant, and by how much was it oversubscribed?

A. It was India's first pharma-sector IPO ever, oversubscribed 10 times

B. It was the first Indian biotech company to go public, oversubscribed 33 times

C. It raised the largest IPO sum in Indian history, oversubscribed 5 times

D. It was the first IPO to list on both the BSE and NSE simultaneously, oversubscribed 15 times

See answer ↓

4. In the December 2025 deal to fully consolidate Biocon Biologics, at what value was the biosimilars unit assessed?

A. $5.5 billion

B. $815 million

C. $10 billion

D. $2.3 billion

See answer ↓

5. In which year did Kiran Mazumdar-Shaw receive the Padma Bhushan, India's third-highest civilian award?

A. 1989

B. 2005

C. 1998

D. 2016

See answer ↓

6. In which year was the Department of Biotechnology (DBT) established?

A. 1982

B. 1986

C. 1994

D. 2008

See answer ↓

7. The Union Cabinet approved the BioE3 Policy, India's first dedicated national biotechnology policy, on which date?

A. 24 August 2024

B. 15 August 2024

C. 2 October 2024

D. 5 June 2024

See answer ↓

8. Under the BioE3 Policy, which three 'Bioenablers' does the Department of Biotechnology establish?

A. Research Councils, Innovation Cells, and Skill Centres

B. Testing Labs, Certification Centres, and Data Hubs

C. Science Parks, Incubators, and Accelerators

D. Biomanufacturing Hubs, Biofoundries, and Bio-AI Hubs

See answer ↓

Answer Key

1. **D.** Kiran Mazumdar-Shaw founded Biocon in 1978, at age 25, in the garage of her rented house in Bengaluru. ↑ Q1
2. **B.** Biocon began as an industrial enzymes business; in 1979 it became the first Indian company to export enzymes to the US and Europe. It only moved into insulin and biosimilars later. ↑ Q2
3. **B.** Biocon's 2004 IPO was the first Indian biotech company to go public, and was oversubscribed 33 times. ↑ Q3
4. **A.** The December 2025 deal values Biocon Biologics at $5.5 billion; $815 million was specifically the price for buying out Viatris (formerly Mylan)'s separate residual stake, not the whole unit's valuation. ↑ Q4
5. **B.** Kiran Mazumdar-Shaw received the Padma Shri in 1989 and the Padma Bhushan in 2005. ↑ Q5
6. **B.** The correct answer is **1986**. Prime Minister Rajiv Gandhi set up DBT in 1986, inside the Ministry of Science and Technology. The 1982 option is wrong because that is the year of the National Biotechnology Board, which came first. The 1994 option is wrong because no source gives that year. The 2008 option is wrong because that is when the BRCP began. Memory hook: board in 1982, department in 1986. ↑ Q6
7. **A.** The Union Cabinet approved the BioE3 Policy on 24 August 2024, to foster high-performance biomanufacturing in India. ↑ Q7
8. **D.** BioE3 works through three types of Bioenablers: Biomanufacturing Hubs, Biofoundries, and Bio-AI Hubs. ↑ Q8

Quick-check answers

1. **False.** ↑ 1
2. **True.** ↑ 2

Curated by Arsalan Zuberi · mcqquestion.com

Scan to read online

https://mcqquestion.com/articles/indeco0143-kiran-mazumdar-shaw/